Natera, Inc. logo

Natera, Inc. Balance Sheet Statement

Assets, liabilities, and shareholders' equity

Natera, Inc. holds $2.6B in total assets. Shareholders' equity is $1.8B against $320.4M in total debt. Cash and equivalents total $1.1B. The current ratio is 2.96 and debt-to-equity is 0.181. Based on the Q1 2026 filing.

Latest FilingQ1 2026
Report Date2026-05-08
Market Cap$27.6B
ROE-22.6%

Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accounts payable$34.9M$39.2M$36.9M$46.5M$33.2M$62.4M
Accrued expenses$62.1M$47.1M$55.0M$77.4M$92.6M$143.8M
Accrued Litigation$32.6M$33.0M
Accrued Manufacturing Costs$62.1M$47.1M$55.0M$77.4M$92.6M$143.8M
Accrued Marketing and Advertising Expenses$20.2M$27.6M
Accrued Progress Collections and Price Adjustments$16.8M$17.1M$17.0M
Contract liabilities$16.8M$17.1M$17.0M
Compensation and benefits$62.1M$47.1M$55.0M$77.4M$92.6M$143.8M
Other accrued liabilities$146.9M$178.4M$191.0M$216.0M$188.7M$212.5M
Current portion of long-term debt$80.4M$80.3M$80.3M$80.3M$80.3M$80.3M
Deferred revenue$19.8M$20.6M$21.6M$21.8M$24.9M$36.9M
Lease Liability Payments - 2020 (Remaining Three Months)$18.6M
Operating Lease Liability Payments - 2024 (Lessee)$27.5M
Operating Lease Liability Payments - 2025 (Lessee)$28.0M
Lease Liability Payments - Due Year Two$27.5M
Lease Liability Payments - Due Year Three$27.6M
Lease Liability Payments - Due Year Four$28.0M
Lease Liability Payments - Remainder of Fiscal Year$24.6M
Note payable to DIRECTV$146.9M$178.4M$191.0M$216.0M$188.7M$212.5M
Operating lease liabilities, current$10.2M$12.2M$13.1M$14.0M$15.6M$14.8M
Operating Lease Liability Payments Due$204.5M
Operating Lease Liability - Undiscounted Excess Amount$44.7M
Professional Service Fees Payable$56.1M$59.0M
Short-term borrowings$80.4M$80.3M$80.3M$80.3M$80.3M$80.3M
Total current liabilities$344.0M$365.7M$384.8M$442.0M$441.2M$558.3M

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Cumulative Cost Basis$1.1B$1.1B
Line of Credit Remaining Borrowing Capacity$20.0M
Accrued charges for third-party testing$20.9M$3.4M
Clinical trials and studies$14.5M$19.6M
Property and equipment purchases$11.3M$22.4M
Accrued Insurance Current And Noncurrent$9.5M$9.7M
Accrued Professional Fees Current And Noncurrent$56.1M$59.0M
Accrued shipping charges$3.4M$2.0M
Accrued third-party service fees$9.8M$20.5M
Testing and laboratory materials from suppliers$12.4M$21.1M
Allowance for doubtful accounts$8.0M$7.9M
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax$0.0$0.0
Gross Unrealized Gains$0.0$0.0
Total$1.1B$1.1B
Available for sale investments$1.1B$1.1B
Business Combination, Contingent Consideration, Liability$118.4M$125.6M
Clinical samples payable$3.7M
Common stock, par value (in dollars per share)$0.0$0.0
Common stock, shares authorized (in shares)$750.0M$750.0M
Common stock, shares issued (in shares)$139.7M$142.7M
Common Stock, Shares, Outstanding$139.7M$142.7M
Contract with Customer, Liability$36.6M$37.3M$42.0M$53.9M
Debt instrument, collateral amount$150.0M
Debt Securities, Available-for-Sale, Allowance for Credit Loss$0.0$0.0
Deferred Tax and Other Liabilities, Noncurrent$701.0K$701.0K
2031 and thereafter$232.0M
Finite-Lived Intangible Assets, Accumulated Amortization$4.9M$12.0M
2028$28.6M
2030$28.3M
Remainder of 2026$21.5M
2027$28.6M
2029$28.3M
Gross Carrying Amount$378.6M$379.4M
Goodwill, Gross$141.1M
Lessee Operating Lease Liability Payments Due$204.5M
2031 and thereafter$78.2M
Lessee Operating Lease Liability Undiscounted Excess Amount$44.7M
Estimated litigation liability$32.6M$33.0M
Operating Lease Weighted Average Discount Rate Percent$0.1
Other accrued expenses$6.8M$3.0M
Purchase Obligation$261.4M
Sales and income tax payable$8.4M$9.4M
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number$3.6M$3.2M
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price$27.0$28.8
Penalties and interest accrued on unrecognized tax benefits$0.0$0.0
Purchase Obligation$261.4M
Remainder of Fiscal Year 2024$18.6M
Remainder of Fiscal Year 2025$21.5M